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Abstract: Eosinophil migration from circulation
is controlled, in part, by chemokines through a
family of G-protein-coupled chemokine recep-
tors (CCR). Studies of human eosinophils have
demonstrated that signaling through CCR3 re-
ceptors is a prominent pathway leading to che-
motaxis, although several other receptor-ligand
interactions also appear to mediate eosinophil
recruitment. The availability of genetically
unique strains of mice permits a reductionist ap-
proach to assess the signaling pathways in exper-
imental models of human disease. However, de-
spite similarities in these pathways between mice
and humans, signiﬁcant species differences exist,
complicating the translation of results from ani-
mal models to humans. Puriﬁed mouse eosino-
phils were used in this study to investigate the
chemokine receptor expression and the activities
of 18 chemokines. Mouse eosinophils isolated
from IL-5 transgenic mice expressed transcripts
encoding the chemokine receptors CCR1, CCR2,
CCR3, CCR5, CCR8, CXCR2, and CXCR4, but
not CCR4. Mouse eosinophils also migrated in
response to human and mouse eotaxin-1 and -2,
but not human eotaxin-3. In addition, the in-
duced migration of mouse eosinophils by TARC,
MIP-1, and KC suggests that unidentiﬁed recep-
tor-ligand interactions contribute to eosinophil re-
cruitment. It is interesting that the potent chemoat-
tractant of human eosinophils, RANTES, was unable
to mediate mouse eosinophil migration. Further-
more, despite the ability of MIP-1 to bind receptors
on puriﬁed mouse eosinophils, it was only able to
induce signiﬁcant eosinophil migration in a mixed
splenocyte population and was unable to induce mi-
gration of highly puriﬁed eosinophils. Collectively,
these observations reveal physiologically relevant dis-
tinctions in mechanisms mediating human and mouse
eosinophil migration that potentially reﬂect evolu-
tionary disparities between these species. J. Leukoc.
Biol. 71: 1033–1041; 2002.
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INTRODUCTION
Eosinophils are granulocytic leukocytes that selectively accu-
mulate in tissues in a variety of disease states, including
helminth infestations and allergic inﬂammatory responses (e.g.,
asthma and allergic dermatitis, rhinitis, and conjuctivitis).
These bone marrow-derived cells are released into peripheral
blood before migrating into tissues where they exert effector
functions through multiple, often concurrent, mechanisms [1].
The signals and mechanisms controlling the chemoattractant-
mediated migration to sites of inﬂammation depend, in part, on
dynamic interactions between adhesion molecules expressed
on eosinophils as well as the vascular endothelium. In addition,
the generation of chemoattractive signaling gradients within
target tissues appears to be critical for the selective movement
of eosinophils [2].
The use of mouse models to dissect pathways of allergic
inﬂammation and determine the roles of individual cell types
and chemokines/chemokine receptors in allergic pathophysi-
ology has increased dramatically. The ability of these models to
develop antigen-induced recruitment of lymphocytes and eo-
sinophils [3], increase antigen-speciﬁc immunoglobulins, and
increase T-helper cell type 2 cytokines and chemokines [4–6],
coupled with the ease of genetic manipulation in these animals
(for example, see ref [7]), has led to the widespread use of mice
as models of human allergic inﬂammation. The expanded use
of mouse models has thus necessitated a more thorough exam-
ination of chemokine-eosinophil interactions in mice in order
to gain a better understanding of how these responses may
differ from those responses in humans.
Chemokines are a family of small peptides (8–14 kD) pro-
duced by many cells involved in allergic inﬂammation, includ-
ing endothelial cells [8, 9], epithelial cells [10], ﬁbroblasts
[11], smooth muscle [12, 13], monocytes/macrophages [14], T
cells [15], mast cells [16], and eosinophils [15]. Chemokines
act by binding to cells through G-protein-coupled seven-trans-
membrane receptors on leukocytes, which promote an array of
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integrin activation, cytoskeletal reorganization, degranulation,
and the generation of oxygen radicals and bioactive lipids [17].
Human eosinophils have been shown to express the chemokine
receptors CCR1 [18], CCR3 [18, 19], CXCR2 [20], and CXCR4
[21]. In turn, several chemokines have been shown to elicit the
migration of human eosinophils through several CC-chemokine
receptors including eotaxin-1 [22], -2 [23], and -3 [24]; mono-
cyte-chemotactic protein (MCP)-2 [25], -3 [26], and- 4 [27];
regulated on activation, normal T cell expressed and secreted
(RANTES) [28]; macrophage inﬂammatory protein (MIP)-1
[29]; interleukin (IL)-8 [20]; and macrophage-derived chemo-
kine (MDC) [30]. In contrast, mouse eosinophils have only
been shown to express CCR1 and CCR3 [31]. Accordingly,
only mouse eotaxin-1 [32] and -2 [33] (a mouse orthologue of
eotaxin-3 has not been identiﬁed to date) and MIP-1 [31]
have been shown to have effects on mouse eosinophil migra-
tion.
Nominal amounts of data characterizing mouse eosinophil
migration in response to chemokines exist as a result of logis-
tical constraints associated with the availability of peripheral
blood eosinophils in sufﬁcient numbers and purity for experi-
mental manipulation. As a result, the available data are not
comprehensive and are found as part of several independent
studies, making it difﬁcult to assess the relative potencies of
the chemokines examined. In this study, IL-5 transgenic mice
were used to generate pure (98%) populations of peripheral
blood eosinophils to investigate the ability of several chemo-
kines to induce migration in vitro. These data demonstrate that
although mouse eosinophils express CCR1 and CCR3, only
responses to CCR3 agonists were signiﬁcant using puriﬁed
eosinophils. CCR1 ligands MIP-1 and RANTES were unable
to elicit migration of puriﬁed eosinophils. Chemokines pre-
sumed to bind to CCR4/CCR8 [m thymus and activation-
regulated chemokine (TARC) and m MIP-1] and CXCR2 (m
KC) also demonstrated abilities to elicit puriﬁed eosinophil
migration. Moreover, the response to TARC was accompanied
by an increase in intracellular calcium ﬂux, suggesting the
presence of an additional chemokine receptor on mouse eosin-
ophils.
MATERIALS AND METHODS
Reagents
All studies were performed with chemokines purchased from R&D Systems
(Minneapolis, MN) with the exception of Figures 3A and 4, in which the mouse
eotaxins 1 and 2 were obtained from PeproTech (Rocky Hill, NJ).
125I-
radiolabeled MIP-1 and eotaxin were purchased from Perkin Elmer Life
Sciences (Boston, MA). HEPES (N-[2-hydroxyethyl]piperazine-N-[2-ethane-
sulfonic acid]), PIPES (piperazine-N,N-bis[2-ethane-sulfonic acid]), EDTA
(ethylenediaminetetraacetic acid), EGTA (ethylene glycol-bis[-aminoethyl
ether]tetraacetic acid), digitonin, Percoll, and glucose were purchased from
Sigma Chemical Co. (St. Louis, MO). Fura-2 acetoxymethyl ester was pur-
chased from Molecular Probes (Eugene, OR). Fetal calf serum (FCS), Hank’s
balanced salt solution (HBSS), and Dulbecco’s phosphate-buffered saline
(PBS) were purchased from Gibco Life Technologies (Rockville, MD). Anti-
CD45 and -CD90 antibody conjugated magnetic beads were obtained from
Miltenyi Biotech (Auburn, CA).
Mice
IL-5 transgenic mice, line NJ.1638, were generated as described previously
[34]. All procedures were conducted on speciﬁc pathogen-free mice 4–6
months of age that were maintained in ventilated microisolator cages housed in
an AAALAC-accredited animal facility. Protocols and studies involving ani-
mals were conducted in accordance with National Institutes of Health and
Mayo Clinic Foundation guidelines.
Isolation of mouse eosinophils
We have developed methods to isolate eosinophils to greater than 98% purity
from the IL-5-expressing transgenic line NJ.1638 [34]. Constitutive expression
of IL-5 in these mice leads to a marked increase in circulating total white blood
cells as well as a compositional shift to nearly 60% eosinophils. As a conse-
quence, greater than 5  10
8 eosinophils can be recovered from 2 ml blood.
Cells were routinely obtained from NJ.1638 mice by collecting 300–400 l
tail blood from each of four mice into 5 ml PBS containing 2% heparin. The
blood was then layered onto a single-step Percoll gradient [60% Percoll
(1.084), 1HBSS, 15 mM HEPES (pH 7.4)] and was centrifuged (45 min,
2000 g,4 °C). The buffy coat containing lymphocytes and eosinophils was
removed and washed twice in PBS containing 2% FCS. The cell pellet was then
subject to brief hypotonic lysis in order to disrupt any contaminating red blood
cells, then washed and resuspended in PBS containing 2% FCS. Eosinophils
were subsequently isolated by removing the contaminating lymphocytes using
a magnetic cell-separation system (Miltenyi Biotech), according to the manu-
facturer’s recommendations. Brieﬂy, B cells and T cells were removed by
positive selection following incubation with antibody conjugated magnetic
beads speciﬁc for CD45-R (B220) and CD90 (Thy 1.2), which bind B cells and
T cells, respectively. Recovered cells were washed twice, resuspended in
RPMI 1640, and maintained at a concentration of 1  10
7 cells/ml at 4°C. The
purity of the recovered cells was determined by visual examination of Wright’s
stained cytospin preparations. Cell viability was determined each day by
trypan blue exclusion.
Splenocyte isolation
Splenocytes were isolated from nontransgenic littermates. Brieﬂy, spleens were
removed and placed in RPMI-1640 media containing 2% FCS. Single cell
suspensions were obtained by passing a suspension of splenocytes repeatedly
through a 22-gauge needle and 40 m ﬁlter. Viability of the cells was 95%
as determined by trypan blue exclusion.
Receptor-binding assays
Binding of
125I-labeled chemokines (typically a total of 210
4 cpm) to intact
mouse eosinophils (typically 510
5)a t3 1 °C for
125I-eotaxin, or room temper-
ature for
125I-labeled MIP-1, was performed in the presence of varying
concentrations of unlabeled ligands essentially as described [18].
Reverse transcriptase-polymerase chain reaction
(RT-PCR) ampliﬁcation of chemokine receptor
RNA
Total RNA was isolated from puriﬁed eosinophils using Trizol reagent (Gibco
Life Technologies) according to the manufacturer’s protocol. Puriﬁed RNA was
stored at 	80°C until reverse transcribed. Reverse transcription and the
generation of PCR amplicons representing individual mouse chemokine re-
ceptors (CCR1, CCR2, CCR3, CCR4, CCR5, CCR8, CXCR2, and CXCR4)
were performed as described previously by Fischer et al. [35]. Total RNA that
was not reverse transcribed served as the negative control in the PCR ampli-
ﬁcation. PCR products were visualized on a 1.2% agarose gel following
staining with ethidium bromide.
Transmigration assay
The migration of puriﬁed eosinophils or splenocytes in response to various
chemokines in vitro was investigated using 5 m polycarbonate membrane
Transwell inserts in 24-well tissue-culture polystyrene plates (Costar, Corning,
NY). The inserts were preincubated with media (RPMI 1640 containing 5%
FCS) for 1 h. Media was removed, and cells (110
6; puriﬁed eosinophils
included 30 ng/ml recombinant mouse IL-5), in a total volume of 200 l media,
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containing 500 l media alone or media containing chemokines. The plates
were incubated at 37°C and 5% CO2 for 90 min. Assay conditions including
cell number, FCS, and IL-5 concentrations and incubation time were optimized
using mouse eotaxin-1 and mouse RANTES.
The number of cells that had migrated in these Transwell assays was
determined as the sum of the cells in the lower chamber plus the cells that had
migrated but remained attached to the bottom of the Transwell insert. Cells that
had migrated through the insert and were in the lower chamber were collected
into a microcentrifuge tube. The cells that had migrated to the lower chamber,
but remained attached to the insert, were recovered by initially removing the
cells in the upper chamber, as well as any remaining suspension (by wiping
with a cotton-tipped applicator). The attached cells were then recovered by
placing the bottom of the inserts into 500 l ice-cold PIPES buffer containing
5 mM EDTA and tapping the plates lightly. The cells displaced from the
membrane were added to the corresponding microcentrifuge tubes containing
lower chamber cells and were counted using a Coulter particle counter (Model
Z1, Beckman/Coulter, Fullerton, CA). Differential counts for splenocyte mi-
gration were determined by counting Wright’s stained cytospin slides (Cytospin
3, Shandon Scientiﬁc, Pittsburg, PA) counting 300 cells. Cell migration is
expressed as a migration index, which is the ratio of the number of cells
migrating in reponse to chemokine relative to the number of cells migrating in
response to media alone.
Intracellular calcium measurements
Eosinophils (110
6 cells/ml) were loaded with 2 M Fura-2 in RPMI 1640
containing 2% FCS and were incubated in the dark for1ha t3 7 °C. Cells were
washed twice in assay buffer (HBSS containing 1 mM CaCl2), resuspended at
1  10
6 cells/ml, and used within 1 h. The cytoplasmic-free Ca
2
 concentra-
tion of continually stirring cells (210
6/2 ml) in response to various chemo-
kines was measured using a Hitachi F-4500 spectroﬂuorometer with excitation
at 340 nm and 380 nm and emission at 510 nm. Data are presented as a ratio
of ﬂuorescence at 340 nm and 380 nm. Maximal and minimal values were
obtained by lysing the cells with 20 M digitonin and chelation with 10 mM
EGTA, respectively.
Alignment and phylogenetic analysis
Nucleotide and amino acid sequences were obtained from Genbank using
published accession numbers. Amino acid sequences were aligned using
CLUSTAL with a gap penalty of 5.0 [36]. In addition, Blossum and Pam and
Gonnet amino acid weight matrices were used in the different alignments.
Alignments with the various amino acid weight matrices did not differ drasti-
cally, so we report only those results using the Blossum weighting matrix. Once
the amino acid alignments were obtained, the nucleic acid sequences were
adjusted to reﬂect the insertion of gaps in the amino acid alignments [37].
Because the gaps that were introduced into the nucleic acid sequences cover
more than a single base, we recorded these gapped regions as single characters
as in DeSalle and Brower [38]. Mouse B-lymphocyte chemoattractant was used
as an out-group gene to polarize the relationships of the chemokines compris-
ing the remaining in-group genes. The presented phylogenetic analyses were
performed with the aligned sequences using a gap penalty of 5. Trees derived
from alignments using a wide range of gap penalties (5, 25, 50, 100) were
relatively consistent. The nucleic acid characters and the recorded gaps were
analyzed together using a single matrix and jackknife resampling analysis, with
1000 sampling replicates, to assess the robustness of the phylogenetic analysis
using the program PAUP [39].
Statistical analysis
Data presented are the means  SE. Statistical analysis was performed on
parametric data using t-tests with differences between the means considered
signiﬁcant when P  0.05.
RESULTS
Isolation and viability of eosinophils from IL-5
transgenic mice
Eosinophils isolated from the peripheral blood of IL-5 trans-
genic mice exhibit the morphology of mature, terminally dif-
ferentiated metamyelocytes. The nuclei are heterochromatic,
predominantly ring-shaped, and appear occasionally as “ﬁgure
8”-like structures. The cytoplasm contains a preponderance of
eosin-staining secondary granules and had no basophilic stain-
ing properties. The purity of isolated eosinophils was greater
than 98% [contaminating cells included neutrophils (1%) and
monocytes (0.5%)], and the cells lost little to no viability for
more than 72 h after isolation when maintained at 4°C( Fig.
1A). In vitro Transwell migration in response to eotaxin was
also not signiﬁcantly decreased for at least 72 h following
isolation (Fig. 1B).
Chemokine receptor expression on mouse
eosinophils
RT-PCR was used to examine chemokine receptor gene ex-
pression in puriﬁed mouse eosinophils. mRNA encoding the
mouse chemokine receptors CCR1, CCR2, CCR3, CCR5,
CCR8, CXCR2, and CXCR4 was detected, whereas CCR4
mRNA was undetectable (Fig. 2A). Equilibrium-binding stud-
ies performed on puriﬁed mouse eosinophils using MIP-1 and
eotaxin-1 demonstrate that receptors for these chemokines are
expressed on these cells and bind their cognate ligands with an
approximate equal afﬁnity (IC50  1 nM; Fig. 2B).
Mouse eosinophils migrate in response to
chemokines predominantly through CCR3
receptors
The ability of known CCR1 and CCR3 ligands to mediate
eosinophil migration was assessed using m eotaxin-1, m
eotaxin-2, m RANTES, and m MIP-1 in a transmigration
assay. Mouse eotaxin-2 was the most potent chemokine exam-
ined, reaching a 17-fold increase in maximal response at 30
nM (Fig. 3A). [We observed that the mouse eotaxin-2 obtained
from R&D Systems had minimal activity compared with mouse
eotaxin-2 obtained from PeproTech. Therefore, the studies that
make a quantitative assessment of eotaxin potency (Figs. 3A
and 4) were conducted with the PeproTech chemokines.] Sur-
Fig. 1. Eosinophils isolated from IL-5 transgenic mice are viable and respon-
sive for several days. (A) Puriﬁed eosinophils (98%) were maintained in
RPMI 1640 at 4°C, and viability was determined on the indicated days by
trypan blue exclusion. Values presented are representative of three separate
determinations. (B) Eosinophil migration in response to 10 nM mouse
eotaxin-1 was assessed for 72 h following cell isolation. Values presented are
means  SE of ﬁve determinations conducted in duplicate.
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no signiﬁcant effects on the migration of puriﬁed eosinophils at
any concentration (0.1–300 nM). However, in contrast to the
studies using puriﬁed eosinophils, m MIP-1 demonstrated a
nominal effect on eosinophil migration in studies using a mixed
population of leukocytes derived from the spleen (Fig. 3B). In
comparison, regardless of the leukocyte population used (i.e.,
pure eosinophils or mixed leukocytes), RANTES failed to
elicit eosinophil migration (Fig. 3). Signiﬁcantly, MIP-1 and
RANTES induced signiﬁcant migration of speciﬁc mononu-
clear subpopulations, demonstrating the functionality of these
chemokines in this assay system.
Non-CCR3 binding chemokines induce
eosinophil migration
Several additional chemokine ligands shown to act through
other receptors were similarly tested. Eighteen chemokines
originally were screened at concentrations of 30 nM and 100
nM. The rank order of potencies was identical at both doses,
and thus the results at 100 nM were arbitrarily chosen and are
shown in Figure 4. Chemokines thought to bind to CCR3
(eotaxins and human MCP-4), with the exception of human
eotaxin-3, showed the greatest responses in the transmigration
assay. Moreover, only three other chemokines (m TARC, m
MIP-1, and m KC) showed signiﬁcant activity (more than
twofold). The baseline migration for all assays presented was
consistently approximately 1% of total cells.
TARC induces a calcium ﬂux in puriﬁed mouse
eosinophils
The ability of m TARC, m MIP-1, and m KC to bind and
signal speciﬁcally through eosinophil cell surface receptors
was assessed indirectly by measuring intracellular calcium
changes following exposure to these chemokines. Mouse
eotaxin-1, mouse eotaxin-2, and m TARC caused immediate
and signiﬁcant increases in eosinophil intracellular calcium
levels (Fig. 5). In contrast, m MIP-1 and m KC failed to
induce a signiﬁcant calcium ﬂux. Similar results were observed
at 24, 48, and 72 h post isolation for all chemokines examined.
Sequence identity and evolutionary relationship
between chemokines
Sequences derived from a representative sample of the ex-
panded family of mouse and human chemokines were sub-
Fig. 2. Multiple chemokine receptors are expressed on eosinophils derived
from IL-5 transgenic mice. (A) RT-PCR ampliﬁcation of mouse eosinophil
RNA reveals the expression of several CC and CXC chemokine receptors. (	)
Non-RT controls. (B) Competitive ligand-binding studies were performed on
puriﬁed eosinophils. Leukocytes were incubated with
125I-labeled human
eotaxin or human MIP-1 and increasing concentrations of unlabeled
eotaxin-1 or MIP-1. Values presented are means  SE of duplicate determi-
nations conducted in triplicate.
Fig. 3 Puriﬁed mouse eosinophils migrate in
response to mouse eotaxins but not mouse
RANTES or MIP-1. (A) Puriﬁed mouse eosin-
ophil and (B) mouse splenocyte migration in
response to these CCR1- and CCR3-binding
chemokines were assessed using a Transwell
insert assay system, and the data are expressed
as a migration index (see Materials and Meth-
ods). Values presented are means  SE of du-
plicate determinations conducted on three sep-
arate occasions. *, Signiﬁcantly different
(P0.05) from baseline.
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speciﬁc evolutionary relationships among these chemoattrac-
tive cytokines (Fig. 6A). The amino acid sequences of these
proteins as well as the nucleotide sequences of the respective
genes were used in jackknife resampling analyses to generate
a molecular cladogram describing the evolutionary relation-
ships among these chemokines (Fig. 6B). These analyses yield
relatively stable relationships among the 18 genes/proteins
assessed and show that nearly all chemokines with substantive
agonist activities on mouse eosinophils belong to a single clade
with high jackknife support. The most parsimonious mapping
of agonist activities in the cladogram of Figure 6B was to
assume that the activities arose independently in all lineages
where activity occurs and to assume ﬁve independent evolu-
tionary gains of agonist activity.
DISCUSSION
Three human eotaxin genes (eotaxin-1 [40], eotaxin-2 [41], and
eotaxin-3 [24]) and two known mouse eotaxin genes (eotaxin-1
[32] and eotaxin-2 [33]) have been identiﬁed and characterized
as CCR3 ligands. Surprisingly, the sequence identity among
these eosinophil-selective chemokines is only 34–39% within
either species, and although human and mouse eotaxin-1 and
-2 are likely orthologous pairs (each pair displaying 60%
identity), a mouse orthologue of human eotaxin-3 has yet to be
identiﬁed. Although CCR3 has also been identiﬁed on human
mast cells, basophils, and T cells, the only mouse leukocyte
shown to express CCR3 is the eosinophil [42]. In vitro migra-
tion assays using puriﬁed mouse eosinophils demonstrated that
mouse eotaxin-1 reached half-maximal responses at similar
doses to eotaxin-2; however, the maximal responses to mouse
eotaxin-2 were higher relative to eotaxin-1. The increased
response of mouse eosinophils to eotaxin-2 compared with
eotaxin-1 parallels previous studies of human eosinophils not-
ing a similar pattern of chemokine responsiveness [41], but is
in contrast to a recent study characterizing mouse eotaxins
using mixed splenocytes from IL-5 transgenic mice, which
demonstrates eotaxin-1 to be more potent than eotaxin-2 [33].
These differences are likely attributable to the cell populations
studied. The data presented here and the studies on human
eotaxins used eosinophils that were puriﬁed to 98%, whereas
the conﬂicting study [33] used a population of cells that were
only 30–40% eosinophils. Human MCP-4 was also a potent
chemokine, exhibiting signiﬁcant activity toward mouse eosin-
ophils and consistent with its demonstrated activity for human
eosinophils [27]. This is not unexpected given that MCP-4
shares high sequence identity with mouse and human eotaxin-1
and binds CCR3. Human eotaxin-3 is the only chemokine of
this group not to exert effects on mouse eosinophil migration.
However, because human eotaxin-3 has only been reported to
induce human eosinophil migration at a high dose (1 M) [24],
the lack of effects at the nanomolar concentrations used in this
study is not surprising.
The data presented here demonstrate that although MIP-1
can bind to puriﬁed mouse eosinophils, this chemokine is
Fig. 4. Mouse eosinophils migrate in response to CCR3 and non-CCR3
ligands. Eosinophil migration in response to various chemokines (100 nM) was
investigated using a Transwell insert assay system. Data are expressed as a
migration index, as described in Materials and Methods. All chemokines were
purchased from R&D Systems with the exception of m eotaxin-1 and m
eotaxin-2 (PeproTech). Values presented are means  SE of duplicate deter-
minations conducted on three separate occasions. *, Signiﬁcantly different
(P0.05) from baseline.
Fig. 5. TARC induces intracellular calcium ﬂux
in puriﬁed eosinophils. Calcium ﬂux was assessed
in eosinophils exposed to chemokines at concen-
trations that induced in vitro migration: (A) m
eotaxin-1 (30 nM), (B) m eotaxin-2 (30 nM), (C) m
TARC (100 nM), (D) m MIP-1 (100 nM), and (E)
m KC (100 nM). Arrows indicate addition of che-
mokine. Data are presented as ratio of ﬂuores-
cence at 340 and 380 nm. Scale bar equals a
340/380 ﬂuorescence ratio of 1. Data are repre-
sentative of values obtained from independent
experiments conducted on at least three separate
occasions.
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is reﬂective of the literature that abounds with conﬂicting data
concerning the ability of MIP-1 to induce human eosinophil
migration [18, 29, 43–46] or eosinophil recruitment in mouse
models [6, 31, 47, 48]. In the case of human eosinophils, the
study by Sabroe et al. [45], examining eosinophils from mul-
tiple donors, provides an explanation to resolve this issue by
demonstrating that MIP-1 responses are only observed in
20% of individuals. The studies in mice have been particu-
larly problematic because these in vitro studies have been
performed on eosinophils whose purity varied from 30% to
99%, and so possible indirect effects of MIP-1 on other cell
types may have inﬂuenced eosinophil migration. This hypoth-
esis is supported by the present study in which MIP-1 has no
effects on puriﬁed eosinophils, but exerts some effect on eo-
sinophils when they are studied as a mixed population of
leukocytes. The sensitivity of this effect is apparently signiﬁ-
cant, because even in a mouse eosinophil assay system, com-
parable with the one used here, Post and colleagues [31]
demonstrated that MIP-1 elicits a small (approximately two-
Fig. 6. Amino acid sequence alignment and
evolutionary relationships between mouse and
human chemokines. (A) Amino acid alignment
of the chemokines examined for eosinophil ac-
tivity. The letters above the alignment (a–g)
indicate positions that were recoded as de-
scribed in Materials and Methods. (B) Molecu-
lar cladogram derived from analyses using par-
simony for matrices generated with a gap pen-
alty of 5.0. The cladogram is a strict consensus
product of two parsimony trees. The numbers on
the nodes indicate the percentage of replicates,
where the node is retained in the jackknife
resampling. Arrows indicate nodes where che-
mokine agonist activity is mapped in the most
parsimonious scenario. Nucleotide and amino
acid sequences were obtained from Genbank
accession numbers as follows: mouse eotaxin-2
(AF244367), human eotaxin-2 (U85768),
mouse eotaxin-1 (U40672), human eotaxin-1
(D49372), human MCP-4 (U46767), mouse
TARC (AJ242587), mouse MIP-1 (M35590),
human eotaxin-3 (AB010447), mouse KC
(J04596), mouse MDC (AF052505), mouse C10
(M58004), mouse BLC (AF044196), mouse
TECK (U86358), mouse MIP-1 (U49513),
mouse MIP-3 (AF059208), human RANTES
(M21121), mouse RANTES (M77747), and
mouse MIP-1 (X12531).
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this discrepancy is unclear, but may be associated with the use
of an eosinophil population of lower purity (85–92%) or a
subtle phenotypic difference in eosinophils isolated from trans-
genic mice with different circulating IL-5 levels. This issue
may also complicate the interpretation of in vivo studies that
support MIP-1 as an important chemokine in eosinophil
recruitment as indirect effects of MIP-1, as the mechanism
inﬂuencing tissue eosinophil accumulation, cannot be elimi-
nated [6, 47, 48].
RANTES is a potent human eosinophil chemoattractant [49]
that can bind to CCR1 [50] and CCR3 [18, 19], but appears to
exert its effects on eosinophils primarily through CCR3 [51].
However, RANTES displayed no chemotactic activity on
mouse eosinophils using two different assay systems. This
conclusion is supported by in vivo studies demonstrating that
intradermal injection of eotaxin, but not RANTES, in the
mouse skin recruits eosinophils selectively [47], and trans-
genic overexpression of RANTES in the mouse lung recruits
neutrophils selectively, but not eosinophils [52]. It is interest-
ing that mouse RANTES is unable to displace
125I-eotaxin
binding on mouse CCR3 transfected cells (B.L.D., unpublished
results), suggesting that the loss of chemotaxis induced by
mouse RANTES is a consequence of the inability to bind
mouse CCR3. The reason for this disparity is unknown, but
likely reﬂects evolutionarily signiﬁcant selective pressures in
one or both species.
The ability of mouse KC, MIP-1, and TARC to induce
eosinophil migration in these assays suggests that additional
chemokine receptors may represent unique pathways for eo-
sinophil migration and function. The biology of KC, in partic-
ular, has been well characterized, and it is known to bind
through the chemokine receptor CXCR2 [53]. The detection of
CXCR2 mRNA in the eosinophils used in this study suggests
that signaling through this receptor is responsible for the
migration induced by KC. It is interesting that human eosino-
phils are known to express CXCR2 when they are cultured in
IL-5 [51], and thus the possibility exists that the eosinophils
used in our studies express functional CXCR2 receptors as
they were isolated from transgenic mice with elevated, circu-
lating IL-5 levels (400 pg/ml). Nonetheless, because circulat-
ing IL-5 levels also increase during allergic inﬂammation,
CXCR2 expression may represent an alternate/additional path-
way facilitating eosinophil recruitment in vivo.
TARC and MIP-1 are the least characterized chemokines
that demonstrated activity on mouse eosinophils. MIP-1 has
been characterized as a ligand for CCR5 [54], and the detec-
tion of mRNA for this receptor in mouse eosinophils may
explain the activity of this chemokine in these studies. The
receptor for TARC mediating the migration of eosinophils
remains problematic as there is conﬂicting evidence for TARC
as a CCR8 ligand [55–57] but strong evidence for TARC as a
CCR4 ligand [58]. Garlisi et al. [55] reported that TARC bound
to CCR8 receptors in transfected cells only at very high (i.e.,
nonphysiologically relevant) concentrations (250 nM) to
compete with the CCR8 ligand I-309. However, in natural
killer (NK) cells, TARC was able to compete away I-309 with
an IC50 of 1.6 nM [57]. This may reﬂect a difference in
transfected versus primary cells or a difference in cell type
receptor usage (T cells vs. NK cells vs. eosinophils). In either
case, no previous evidence exists indicating that these chemo-
kines are eosinophil chemoattractants; instead, both chemo-
kines have been implicated in the responses of T cells during
allergic, inﬂammatory responses [59, 60].
It is interesting that m TARC, but not m KC or m MIP-1,
induced a signiﬁcant calcium ﬂux in puriﬁed eosinophils. An
increased intracellular calcium ﬂux is commonly associated
with chemokine receptor signaling, but there are many studies
that demonstrate chemokine function occurring in conjunction
with low or no calcium ﬂux in various cell types including
eosinophils [19, 30, 56]. Several reasons could account for this
occurrence including calcium-independent signal transduction
pathways utilized by various chemokine receptors or receptor
expression levels being too low to evoke a measurable calcium
ﬂux within the sensitivity of the assay. In the case of CCR3, a
recent study indicates that chemokine binding, intracellular
calcium ﬂux, and migration responses are not coupled tightly
[43]. Furthermore, given that all of the eotaxin chemokines
studied to date bind to eosinophils with similar afﬁnities
(Kd 1–5 nM) [18, 23, 24] but exhibit different efﬁcacies and
potencies in terms of migration, raises the question of how a
chemokine receptor distinguishes between various ligands and
modulates the intracellular signaling pathways necessary to
achieve graded responses.
An important point to consider in the interpretation of these
studies is the possibility that IL-5 has uncoupled or desensi-
tized some of the receptor binding or signaling responses,
which occur normally in eosinophils. This would explain why,
even with strong binding of MIP-1 to the eosinophils, the
binding fails to result in migration. Furthermore, the expres-
sion of chemokine receptors such as CCR2 and CCR5 may
represent “decoy” receptors for ligands like RANTES and
MIP-1, which can bind chemokine but do not elicit intracel-
lular signaling or eosinophil migration. This has been demon-
strated previously on dendritic cells and monocytes exposed
continuously to the cytokine IL-10 [61].
The tertiary structural homology between chemokines ulti-
mately predicts their binding and signaling properties. How-
ever, primary sequence similarities also provide useful data for
the determination of relationships between proteins. The abil-
ity of evolutionarily diverse chemokines outlying the large
eosinophil chemotactic clade (mouse TARC and mouse KC) to
induce eosinophil migration supports the hypothesis that mul-
tiple chemokine signaling pathways have evolved. The com-
monality of chemokines with eosinophil agonist activities in
humans and mice has broad implications and suggests that
these chemotactic mechanisms likely predate the evolution of
the uniquely eosinophil hematopoietic lineage. For example,
CCR3 receptor-ligand interactions represent the dominant sig-
naling pathway leading to eosinophil recruitment in at least two
extant mammalian orders (i.e., Rodentia and Primata), suggest-
ing that the advent of CCR3-mediated eosinophil chemotaxis
occurred before the major radiation of mammalian orders 75–
100 million years ago [62], and thus potentially prior to the
evolution of the mammalian eosinophil hematopoietic lineage.
These studies demonstrate that signiﬁcant differences exist
with regard to the control of eosinophil migration by chemo-
kines between humans and mice and suggest that additional
Borchers et al. Chemokine activities on mouse eosinophils 1039chemokine/receptor interactions may regulate eosinophil mi-
gration. These differences stress the importance of increased
characterization of the mouse as a model of human diseases.
The greater understanding of the mouse as a model system will
no doubt provide invaluable insights regarding eosinophils and
their effector functions in disease.
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